CLINUVEL PHARMACEUTICALS ORD
Clinuvel Showcases AI-Powered Vitiligo Assessment Tool at AAD Conference
Clinuvel unveils AI Vitiligo Visual Algorithm at AAD 2026, linking VVA to CUV107 Phase III; H1 FY26 revenue +4%, PAT -26% on higher costs.
Clinuvel Pharmaceuticals reaches patient recruitment milestone ahead of Phase III Scenesse vitiligo trial
Clinuvel Pharmaceuticals (ASX: CUV) has recruited more than 200 patients for a Phase III trial (CUV105) of its breakthrough Scenesse (afamelanotide 16mg) repigmentation therapy to treat vitiligo. The company is conducting the randomised 20-week trial at 37 sites across North America, Africa and Europe, with 57% of patients enrolled in the US. The last patient […]
Clinuvel reports breakthrough against UV damage in skin DNA repair study using afamelanotide
Specialty pharmaceutical group Clinuvel Pharmaceuticals (ASX: CUV) has received promising outcomes from the final set of results from a study evaluating the DNA-repair capacity of its afamelanotide candidate. For the general population, and specifically for individuals with fair skin types who sunburn easily, the results indicate that afamelanotide can reduce oxidative damage and inflammatory reactions […]
Clinuvel Pharmaceuticals offers up novel drug to combat rare genetic disease following FDA approval
Clinuvel Pharmaceuticals (ASX: CUV) has been given the all-clear to market its afamelanotide drug (brand-named Scenesse) by the US Food and Drug Administration (FDA). The drug was already approved by the European Medicines Agency in 2014 and constitutes the company’s lead compound that combats phototoxicity. The regulatory path to approval has taken over a decade, […]
